Tuberculosis and Respiratory Diseases

  • 제62권5호
  • /
  • Pages.432-436
  • /
  • 2007
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지

Pemetrexed/cisplatin 병합 2차 항암화학요법에 극적 반응을 보인 악성 흉막 중피종 1예

Dramatic Tumor Response to 2nd-line Pemetrexed/Cisplatin Combination Chemotherapy in Patient with Malignant Pleural Mesothelioma

  • 이승민 (건국대학교 의과대학 내과학교실) ;
  • 고순영 (건국대학교 의과대학 내과학교실) ;
  • 서태호 (건국대학교 의과대학 내과학교실) ;
  • 이정현 (건국대학교 의과대학 내과학교실) ;
  • 최승오 (건국대학교 의과대학 내과학교실) ;
  • 이정근 (건국대학교 의과대학 진단영상의학교실) ;
  • 김완섭 (건국대학교 의과대학 병리학교실) ;
  • 이태훈 (건국대학교 의과대학 내과학교실) ;
  • 유광하 (건국대학교 의과대학 내과학교실) ;
  • 이계영 (건국대학교 의과대학 내과학교실)
  • Lee, Seung Min (Department of Internal Medicine, College of Medicine, Konkuk University) ;
  • Ko, Soon Young (Department of Internal Medicine, College of Medicine, Konkuk University) ;
  • Seo, Tae Ho (Department of Internal Medicine, College of Medicine, Konkuk University) ;
  • Lee, Jung Hyun (Department of Internal Medicine, College of Medicine, Konkuk University) ;
  • Choi, Seung Oh (Department of Internal Medicine, College of Medicine, Konkuk University) ;
  • Lee, Jeong Geun (Department of Radiology, College of Medicine, Konkuk University) ;
  • Kim, Wan Seop (Department of Pathology, College of Medicine, Konkuk University) ;
  • Lee, Tae Hoon (Department of Internal Medicine, College of Medicine, Konkuk University) ;
  • Yoo, Gwang Ha (Department of Internal Medicine, College of Medicine, Konkuk University) ;
  • Lee, Kye Young (Department of Internal Medicine, College of Medicine, Konkuk University)
  • 투고 : 2007.03.26
  • 심사 : 2007.05.03
  • 발행 : 2007.05.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

악성 흉막 중피종(Malignant pleural mesothelioma, MPM)은 선암과의 감별이 어렵고 예후가 매우 좋지 않은 드문 암이다. MPM의 치료를 위해 많은 항암제들이 시도되었지만 그 효과는 크지 않았다. 완전관해는 거의 되지 않으며 부분 관해 역시 1/3 이하의 환자에서 기대할 수 있다. 하지만 최근 한 3상 연구를 보면 cisplatin 단독요법에 비해 pemetrexed/cisplatin 병합 항암화학요법이 반응률과 평균 생존기간을 의미있게 증가시켰다. 이에 저자들은 1차 항암화학치료에 실패한 MPM환자에서 pemetrexed/cisplatin 병합화학요법을 시도한 결과 극적인 반응을 보인 1예를 경험하였기에 문헌 고찰과 함께 보고하는 바이다.

Malignant pleural mesothelioma (MPM) is a rare tumor that is difficult to clearly distinguish from an adenocarcinoma but usually has a poor prognosis. Numerous cytotoxic agents have been used in the primary treatment of MPM with limited success. A complete response is unusual and a partial response occurs in less than one-third of patients. Recently, a phase III trial showed that a combination of pemetrexed with cisplatin resulted in a significantly higher response rate and median survival time than with cisplatin alone. We encountered a case of a dramatic tumor response to pemetrexed/cisplatin combination chemotherapy in patients with MPM, which was resistant to the 1st-line gemcitabine/cisplatin therapy. After six cycles of pemetrexed/cisplatin combination chemotherapy, the tumor volume had decreased dramatically with complete symptom relief. There was no chemotherapy-related toxicity or scheduled violation. The patient is under maintenance chemotherapy with the same regimen.

키워드

참고문헌

  1. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003;27:1031-51 https://doi.org/10.1097/00000478-200308000-00001
  2. Moskal TL, Urschel JD, Anderson TM, Antkowiak JG, Takita H. Malignant pleural mesothelioma: a problematic review. Surg Oncol 1998;7:5-12 https://doi.org/10.1016/S0960-7404(98)00019-X
  3. Boutin C, Schlesser M, Frenay C, Astoul P. Malignant pleural mesothelioma. Eur Respir J 1998;12:972-81 https://doi.org/10.1183/09031936.98.12040972
  4. Rusch VW, Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1996;111: 15-25
  5. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol 1996; 4:1007-17
  6. Ryan CW, Herndon J, Vogelzang NJ. A review of chemotherapy trials for malignant mesothelioma. Chest 1998;113:66S-73S https://doi.org/10.1378/chest.113.1_Supplement.66S
  7. Alberts AS, Falkson G, Goedhals L, Vorobiof DA, Van der Merwe CA. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988;6:527-35 https://doi.org/10.1200/JCO.1988.6.3.527
  8. Sugarbaker DJ, Heher EC, Lee TH, Couper G, Mentzer S, Corson JM, et al. Extrapleural pneumonectomy, chemotherapy and radiotherapy in the treatment of diffuse malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1991;102:10-5
  9. Ball DL, Cruickshank DG. The treatment of malignant mesothelioma of the pleura: review of five-year experience, with special reference to radiotherapy. Am J Clin Oncol 1990;13:4-9 https://doi.org/10.1097/00000421-199002000-00002
  10. Allen KB, Faber LP, Warren WH. Malignant pleural mesothelioma: extrapleural pneumonectomy and pleurectomy. Chest Surg Clin N Am 1994;4:113-26
  11. Rusthoven JJ, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1999;17:1194
  12. John W, Picus J, Blanke CD, Clark JW, Schulman LN, Rowinsky EK, et al. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer 2000;88:1807-13 https://doi.org/10.1002/(SICI)1097-0142(20000415)88:8<1807::AID-CNCR8>3.0.CO;2-L
  13. Miles DW, Smith IE, Coleman RE, Calvert AH, Lind MJ. A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. Eur J Cancer 2001;37: 366-71
  14. Thodtmann R, Depenbrock H, Blatter J, Johnson RD, van Oosterom A, Hanauske AR, et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY 231514) in combination with cisplatin. J Clin Oncol 1999;17:3009-16 https://doi.org/10.1200/JCO.1999.17.10.3009
  15. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44 https://doi.org/10.1200/JCO.2003.11.136
  16. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004;15:257-60 https://doi.org/10.1093/annonc/mdh059
  17. Mendelsohn LG, Shih C, Chen VJ, Habeck LL, Gates SB, Shackelford KA. Enzyme inhibition, polyglutamation and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 1999;26:42-7
  18. Schultz RM, Chen VJ, Bewley JR, Roberts EF, Shih C, Dempsey JA. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 1999;26:68-73
  19. Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21:1556-61 https://doi.org/10.1200/JCO.2003.06.122
  20. Monetti F, Casanova S, Grasso A, Cafferata MA, Ardizzoni A, Neumaier CE. Inadequacy of the new response evaluation criteria in solid tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases. Lung Cancer 2004;43:71-4 https://doi.org/10.1016/j.lungcan.2003.07.005
  21. Van Klaveren RJ, Aerts JG, de Bruin H, Giaccone G, Manegold C, Van Meerbeeck JP. Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer 2004;43:63-9 https://doi.org/10.1016/S0169-5002(03)00292-7